Fundraising Fox
🦊/People
Sign in

Robert de Jonge

Chief Business Officer at Mestag Therapeutics

London, England, United Kingdom

Find your path to Robert

233 people in our graph share verified history with Robert — schools, employers, funds. One of them is your warm intro.

Issi RozenunlockedRobert: together at Mestag Therapeutics (2021–2026)
Robert: together at Mestag Therapeutics
×2Robert: together at Delft University of Technology
Robert: together at Merck Serono

Chief Business Officer at Mestag Therapeutics

Intro paths

→

In turn, Robert can intro founders to Mestag Therapeutics's investors below.

Mestag Therapeutics's investors · 6

ForbionNaarden · since 2026GV (Google Ventures)Mountain View · $250K – $50M checks · since 2026JJDCNew Brunswick · $500K – $5M checks · since 2026Johnson & Johnson Innovation – JJDCNew BrunswickNorthpond VenturesBethesda · $100K – $5M checks · since 2026SV Health InvestorsBoston · $1M – $20M checks · since 2026

Co-founders at Mestag Therapeutics

SHSusan Hill
Susan HillChief Executive Officer
MB
Michael B. BrennerFounder
CB
Chris BuckleyFounder
MCMark Coles
Mark ColesFounder
SR
Soumya RaychaudhuriFounder
DA
David A. TuvesonFounder

Experience

  1. Mestag TherapeuticsChief Business Officercurrent2026 — presentCambridge, England, United Kingdom
  2. Mestag TherapeuticsSVP Head of Corporate Development2024 — 2026Cambridge, England, United Kingdom
  3. Mestag TherapeuticsVP Head of Corporate Development2021 — 2024Cambridge, England, United Kingdom
  4. Cellinta LimitedHead of Corporate Development2020 — 2021
  5. Independent ConsultantIndependent Consultant2020Greater London, England, United Kingdom
  6. Black Belt TX (now Alesta Therapeutics)Chief Executive Officer2018 — 2020Stevenage, United Kingdom
  7. Tusk Therapeutics Ltd (acquired by Roche Sept 2018)Head of Business Development2018Stevenage, United Kingdom
  8. Tusk Therapeutics Ltd (acquired by Roche Sept 2018)Director of Business Development2015 — 2017Stevenage, United Kingdom
  9. reMYND NVHead of the Contract Research Organization2013 — 2015Brussels Area, Belgium
  10. reMYND NVBusiness & Operations Analyst (Business & Finance controller)2011 — 2013Brussels Metropolitan Area
  11. Merck SeronoInvestment Analyst at Merck Serono's Venture Capital Fund2010Geneva, Geneva, Switzerland
  12. S.V. LIFESenior Member of the Financial Control Committee of SV LIFE2006 — 2010Leiden & Delft, The Netherlands
  13. Leiden Amsterdam Center for Drug Research (LACDR)Bioinformatics and Neuroscience Research2009Leiden, The Netherlands
  14. Leiden University Medical CenterOncology Research2008Leiden, The Netherlands
  15. S.V. LIFETreasurer at Study Association LIFE2005 — 2006Leiden & Delft, The Netherlands

Skills & more

Lifesciences30Neuroscience17Molecular Biology21Biotechnology16In Vivo6Teamwork6Bioinformatics7Management4Business Development3Strategic Financial Planning1Business Operations2Business Analysis1
+8 moreProgrammingSciencePerlProtein ChemistryDrug DiscoveryFinancial ModelingFinanceCorporate Finance

Languages Dutch · English

From Robert's professional profile.

Frequently asked questions

Who is Robert de Jonge?
Chief Business Officer at Mestag Therapeutics
Where does Robert de Jonge work?
Robert de Jonge is Chief Business Officer at Mestag Therapeutics.
Where did Robert de Jonge go to school?
Robert de Jonge studied at Delft University of Technology (Master of Science (M.Sc.), Biotechnology); Leiden University (Master of Science (M.Sc.), Biotechnology); Delft University of Technology (Bsc, Life, Science & Technology).

Same school

Shared employers